SeaStar Medical's QUELIMMUNE Honored with National Kidney Foundation's Corporate Innovator Award
TL;DR
SeaStar Medical's QUELIMMUNE device offers a competitive edge by significantly reducing mortality rates in pediatric AKI patients, showcasing innovation in nephrology.
QUELIMMUNE works by targeting the cytokine storm in pediatric AKI patients, connecting to an existing CKRT circuit to regulate the immune response effectively.
QUELIMMUNE improves pediatric AKI treatment outcomes, reducing mortality and long-term dialysis dependency, making a profound impact on children's health and future well-being.
SeaStar Medical's QUELIMMUNE, awarded by the National Kidney Foundation, represents a breakthrough in treating pediatric AKI, with a 77% mortality rate reduction.
Found this article helpful?
Share it with your network and spread the knowledge!
SeaStar Medical's QUELIMMUNE has been recognized with the 2025 Corporate Innovator Award by the National Kidney Foundation (NKF), a testament to its innovative approach in addressing acute kidney injury (AKI) in pediatric patients. This accolade places SeaStar Medical among esteemed past recipients such as Janssen Pharmaceuticals and Merck & Co. Inc., underscoring the significance of QUELIMMUNE's contribution to nephrology.
Acute kidney injury remains a critical challenge in pediatric care, with approximately 4,000 children requiring continuous renal replacement therapy annually and facing mortality rates between 51-58%. QUELIMMUNE, SeaStar Medical's FDA-approved medical device, offers a beacon of hope by targeting the cytokine storm, a dysregulated immune response that exacerbates AKI in pediatric patients with sepsis. The device's approval under a Humanitarian Device Exemption in February 2024 was supported by clinical data showing a 77% reduction in mortality rates and no dialysis dependency after 60 days among treated patients.
The NKF's recognition of QUELIMMUNE underscores the device's potential to transform pediatric AKI treatment. Kevin Longino, CEO of the NKF, emphasized the devastating impact of AKI on children and lauded SeaStar Medical for its contribution to improving patient outcomes. With ongoing trials to evaluate QUELIMMUNE's efficacy in adult AKI patients, SeaStar Medical is poised to extend its impact beyond pediatric care.
The National Kidney Foundation's 75-year legacy of advocating for kidney disease awareness and treatment innovation adds weight to this award. The foundation's efforts have led to significant advancements in kidney care, including the establishment of the Medicare End-Stage Renal Disease benefit. SeaStar Medical's achievement reflects its alignment with the NKF's mission to revolutionize kidney disease treatment and patient care.
Eric Schlorff, CEO of SeaStar Medical, expressed gratitude for the recognition and highlighted the joy of hearing how QUELIMMUNE has saved children's lives. As SeaStar Medical continues to explore QUELIMMUNE's applications, including its potential in treating End-Stage Renal Disease, the company remains committed to addressing unmet needs in nephrology and improving patient outcomes worldwide.
Curated from NewMediaWire
